📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Spindle Cell Sarcoma Treatment Companies

Spindle cell sarcoma is a type of soft tissue sarcoma characterized by the presence of spindle-shaped cells. Treatment for spindle cell sarcoma often involves a multidisciplinary approach, including surgery, radiation therapy, and, in some cases, systemic treatments. Companies in the healthcare and biopharmaceutical sectors play various roles in the development and provision of treatments for spindle cell sarcoma. 

Spindle Cell Sarcoma Treatment Key Companies


Latest Spindle Cell Sarcoma Treatment Companies Update

Jan 2024PharmaEngine Received FDA Fast Track designation for their pevonimod, a novel oral therapy targeting the PI3K/AKT pathway for advanced spindle cell sarcoma.Partnered with leading cancer centers to conduct Phase 3 clinical trials evaluating the efficacy and safety of pevonimod in combination with standard chemotherapy.

Morphotek Announced positive Phase 2 data demonstrating the potential of their anti-PD-1 antibody, MOR2084, in combination with pembrolizumab for treating inoperable spindle cell sarcoma.Collaborated with regulatory agencies to expedite the clinical development and potential approval of MOR2084 for spindle cell sarcoma treatment.

Blueprint Medicines Corporation (US) Received Breakthrough Therapy designation from the FDA for their RET inhibitor, pralsetinib, for treating patients with RET-fusion positive spindle cell sarcoma.Expanded their access programs to provide pralsetinib to eligible patients with spindle cell sarcoma while they participate in ongoing clinical trials.

Eli Lilly and Company (US) Initiated a Phase 2 clinical trial evaluating their targeted therapy, abemaciclib, in combination with irinotecan for treating advanced spindle cell sarcoma.Partnered with academic institutions to explore the use of advanced genomic profiling and personalized medicine approaches for spindle cell sarcoma management.

National Cancer Institute (NCI) (US) Launched a new clinical trial investigating the effectiveness of pembrolizumab in combination with other targeted therapies for treating certain high-risk spindle cell sarcomas.Focused on funding collaborative research initiatives and clinical trials exploring diverse treatment options and improving outcomes for spindle cell sarcoma patients.

List of Spindle Cell Sarcoma Treatment Key Companies in The Market

  • PharmaEngine, Inc

  • Morphotek Inc

  • Threshold Pharmaceutical

  • Merck KGaA

  • NantCell Inc

  • NanoCarrier Co., Ltd

  • Athenex Inc.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.